Hungary: A New Model of Care
One of the most salient challenges crippling Hungary’s effort to move the health agenda forward is the mass exodus of healthcare practitioners—placing significant pressures on an already overwhelmed system. “If…
Who is Janssen? We’re people; more than 35,000, working hard to treat, cure, stop and prevent some of the most devastating and complex diseases of our time — from diabetes and HIV, to Alzheimer’s and cancer.
Janssen is dedicated to addressing and solving some of the most important unmet medical needs of our time in oncology, immunology, neuroscience, infectious diseases and vaccines, and cardiovascular and metabolism. We are driven to action by the plight of patients, and we aspire to make a positive impact on their lives. That’s why we never limit the search for new medicines to our own four walls—we’re always looking to work with partners interested in helping us achieve our goals.
We stay focused on the disease areas where we believe we can make the biggest difference — oncology, neuroscience, immunology, infectious diseases & vaccines, and cardiovascular & metabolism. But success for us doesn’t stop in our labs.
The world is our lab, and we wouldn’t be able to achieve our success if it weren’t for our approach to collaboration. We work closely with like-minded people from researchers to governments, healthcare professionals to patient organizations. And we work with them at every stage, from early discovery to market access and patient education. Our experts collaborate with external parties at every stage of our value chain—from early discovery to market access. We seek medical breakthroughs wherever they occur. Whether you’re at a university, a research organization, or another biotech or pharmaceutical company, we want to hear from you.
We are Janssen. We collaborate with the world for the health of everyone in it.
Contact
Janssen-Cilag Kft.
H-1123 Budapest
Nagyenyed u. 8-14.
Tel.: + 36 1 884-2858
Fax.: + 36 1 884-2939
e-mail: janssenpharmahu@its.jnj.com
One of the most salient challenges crippling Hungary’s effort to move the health agenda forward is the mass exodus of healthcare practitioners—placing significant pressures on an already overwhelmed system. “If…
Hungary operates under a state-owned universal National Health Insurance Fund (OEP), completely financed through mandatory tax contributions from employers and employees. “From a drug reimbursement point of view, we have…
Hungarian collector and producer of blood plasma and plasma-derived therapies HUMAN BioPlazma is rooted in over 60 years of history within the country, but only in 2008, with the influence…
While pharmaceutical products and healthcare financing dominate the majority of discussions surrounding the improvement of health outcomes, health literacy still remains a core issue that, if left unaddressed, may vary…
Preventive healthcare and health literacy are core issues in Hungary that, if left unaddressed, may hinder the country’s ability to push its health agenda forward and create a more sustainable…
Smaller pharma companies in Hungary are looking to new unconventional methods of OTC promotion to sidestep the country’s somewhat restrictive reimbursement scheme and compete with major players in the market. Especially in…
The President of the Doctoral Council of Semmelweis University, Dr. József Timár provides an overview of the healthcare system in Hungary with particular reference to oncology and describes the challenges…
LEO Pharma Hungary’s Andrea Bondár demonstrates the significance of adopting non-traditional methods of promotional activities, and defines how a true intent on understanding the psyche of patients suffering from chronic…
Anita Ordog, GM of Angelini Hungary, discusses the affiliate’s history in the country, their expanding OTC and specialty products portfolio, targeted marketing and sales strategies, and Angelini’s challenging entrance into…
Dr. Lívia Ilku, director of Hungary’s main domestic pharmaceutical manufacturers’ association (MAGYOSZ), describes the current priorities of its member companies and the key factors for success in Hungary; specifically innovation…
Prof. Dr. István Vályi-Nagy, Director General of the United St. Istvan and St. Laszlo Hospitals, shares his insights on running one of the largest hospitals in Hungary and the challenges…
The Managing Director of HUMAN BioPlazma, Ákos Tóth, highlights the transformational growth that the business has experienced since becoming a part of Kedrion Biopharma in 2008, while pinpointing the strategic…
See our Cookie Privacy Policy Here